Genmab Discloses Managerial Share Transactions in Compliance with Regulations

Genmab ( (GMAB) ) has issued an update.

On June 17, 2025, Genmab A/S announced transactions involving shares and linked securities made by its managerial employees and their closely associated persons, in compliance with market abuse regulations. This disclosure highlights the company’s commitment to transparency and regulatory compliance, potentially impacting stakeholder trust and market perception.

The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab’s overall stock score is driven primarily by its strong financial performance, with a robust balance sheet and effective cash flow management. The technical analysis also supports a positive outlook, although the stock may be nearing overbought levels. Valuation metrics are favorable, though the lack of a dividend yield is a minor drawback.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics to improve the lives of patients. Founded in 1999, the company has a strong presence across North America, Europe, and Asia Pacific, and is known for its next-generation antibody technology platforms and a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and immune checkpoint modulators.

Average Trading Volume: 1,415,977

Technical Sentiment Signal: Sell

Current Market Cap: $14.04B

For a thorough assessment of GMAB stock, go to TipRanks’ Stock Analysis page.